31 related articles for article (PubMed ID: 26283687)
1. Genomic and Transcriptomic Analyses of NF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment.
Jour G; Illa-Bochaca I; Ibrahim M; Donnelly D; Zhu K; Miera EV; Vasudevaraja V; Mezzano V; Ramswami S; Yeh YH; Winskill C; Betensky RA; Mehnert J; Osman I
J Invest Dermatol; 2023 Mar; 143(3):444-455.e8. PubMed ID: 35988589
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
Hyman DM; Puzanov I; Subbiah V; Faris JE; Chau I; Blay JY; Wolf J; Raje NS; Diamond EL; Hollebecque A; Gervais R; Elez-Fernandez ME; Italiano A; Hofheinz RD; Hidalgo M; Chan E; Schuler M; Lasserre SF; Makrutzki M; Sirzen F; Veronese ML; Tabernero J; Baselga J
N Engl J Med; 2015 Aug; 373(8):726-36. PubMed ID: 26287849
[TBL] [Abstract][Full Text] [Related]
3. Targeting brain tumor cAMP: the case for sex-specific therapeutics.
Warrington NM; Sun T; Rubin JB
Front Pharmacol; 2015; 6():153. PubMed ID: 26283963
[TBL] [Abstract][Full Text] [Related]
4. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.
Shain AH; Garrido M; Botton T; Talevich E; Yeh I; Sanborn JZ; Chung J; Wang NJ; Kakavand H; Mann GJ; Thompson JF; Wiesner T; Roy R; Olshen AB; Gagnon A; Gray JW; Huh N; Hur JS; Busam KJ; Scolyer RA; Cho RJ; Murali R; Bastian BC
Nat Genet; 2015 Oct; 47(10):1194-9. PubMed ID: 26343386
[TBL] [Abstract][Full Text] [Related]
5. Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.
Korkut A; Wang W; Demir E; Aksoy BA; Jing X; Molinelli EJ; Babur Ö; Bemis DL; Onur Sumer S; Solit DB; Pratilas CA; Sander C
Elife; 2015 Aug; 4():. PubMed ID: 26284497
[TBL] [Abstract][Full Text] [Related]
6. The paradox of cancer genes in non-malignant conditions: implications for precision medicine.
Adashek JJ; Kato S; Lippman SM; Kurzrock R
Genome Med; 2020 Feb; 12(1):16. PubMed ID: 32066498
[TBL] [Abstract][Full Text] [Related]
7. The NF1 gene in tumor syndromes and melanoma.
Kiuru M; Busam KJ
Lab Invest; 2017 Feb; 97(2):146-157. PubMed ID: 28067895
[TBL] [Abstract][Full Text] [Related]
8. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract][Full Text] [Related]
9. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
Krauthammer M; Kong Y; Bacchiocchi A; Evans P; Pornputtapong N; Wu C; McCusker JP; Ma S; Cheng E; Straub R; Serin M; Bosenberg M; Ariyan S; Narayan D; Sznol M; Kluger HM; Mane S; Schlessinger J; Lifton RP; Halaban R
Nat Genet; 2015 Sep; 47(9):996-1002. PubMed ID: 26214590
[TBL] [Abstract][Full Text] [Related]
10. NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma.
Mahalingam M
Adv Anat Pathol; 2017 Jan; 24(1):1-14. PubMed ID: 27941538
[TBL] [Abstract][Full Text] [Related]
11. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
12. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
Cirenajwis H; Lauss M; Ekedahl H; Törngren T; Kvist A; Saal LH; Olsson H; Staaf J; Carneiro A; Ingvar C; Harbst K; Hayward NK; Jönsson G
Mol Oncol; 2017 Apr; 11(4):438-451. PubMed ID: 28267273
[TBL] [Abstract][Full Text] [Related]
13. NF1 Mutations Prevalent but Not Clinically Relevant.
Cancer Discov; 2015 Oct; 5(10):OF1. PubMed ID: 26283687
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
